Biocodex Invests $16.87 Million in Beauvais Live Biotherapeutics Manufacturing Facility Through MRM Health Partnership in France
Biocodex invests €15M in a live biotherapeutics manufacturing plant in Beauvais, France, partnering with MRM Health to support its CORAL®-based microbiome
Research Desk
Biocodex, the independent French pharmaceutical company, will commit USD 16.87 million over the coming years to build a new manufacturing infrastructure dedicated to live biotherapeutic products at its Beauvais site in France, in a strategic partnership announced on November 5, 2026 with Ghent, Belgium-based MRM Health.
Anaerobic Manufacturing in France Backs CORAL-Based Pipeline
The agreement establishes specialized manufacturing capabilities for MRM Health's microbiome-based therapies, including anaerobic manufacturing at Beauvais.
Under the arrangement, Biocodex will fund, build, own, and operate the facility, while MRM Health contributes its proprietary anaerobic manufacturing expertise to the design and implementation.
The infrastructure is designed around the specific requirements of products derived from MRM Health's CORAL platform, while also supporting other live biotherapeutic programs. The collaboration pairs MRM Health's microbiome science with Biocodex's pharmaceutical development, industrialization and manufacturing capabilities.
Supporting MH002 From Clinic Toward Market
The partnership is built to support MRM Health's lead asset MH002 and other CORAL-based programs across the product lifecycle, from process development and clinical manufacturing toward potential future commercial supply.
According to the companies, securing access to specialized manufacturing infrastructure alongside clinical development addresses a future manufacturing and supply requirement for complex live biotherapeutic products and strengthens the readiness of MRM Health's programs for pharmaceutical partnerships and commercialization.
Dr. Sam Possemiers, Chief Executive Officer of MRM Health, said that developing next-generation live biotherapeutics into successful medicines requires manufacturing capabilities as sophisticated as the underlying science.
"Together with Biocodex, we are establishing a specialized and scalable manufacturing pathway from clinical development to future commercial production," he said. "This partnership strengthens the readiness of both our own pipeline and CORAL® programs developed with pharmaceutical partners for future commercialization, bringing us closer to delivering microbiome-based therapeutics to patients."
Nicolas Coudurier, Chief Executive Officer of Biocodex, said the collaboration builds on the partnership the two companies began last year.
"By combining our expertise, we are helping to strengthen European industrial capabilities in the field of live biotherapeutics," he said, describing the deal as an important step in supporting new therapeutic approaches and enabling patients to benefit from them.
Program-by-Program Services With Ownership Preserved
The agreement sets out a framework under which Biocodex may deliver process development, analytical testing, and GMP manufacturing services for individual CORAL programs under program-specific agreements.
MRM Health will hold access to the manufacturing infrastructure for its proprietary, partnered, and outlicensed CORAL programs. The collaboration is explicitly non-exclusive, preserving MRM Health's ability to engage additional or alternative manufacturing partners where appropriate.
The companies describe this flexibility as providing an additional manufacturing pathway for MH002 and the broader pipeline, while reducing the need for MRM Health's pharmaceutical partners to establish specialized manufacturing pathways on their own as programs move toward commercialization.
Both companies also stressed that MRM Health retains ownership of its platform and product-related innovations.
A Timetable From 2027 to Commercial Scale in 2030
MRM Health has built proprietary expertise in the scalable manufacturing of complex bacterial consortia through its single-process CORAL production technology.
The new infrastructure will combine this proficiency with Biocodex's industrial experience, creating what the companies call a coordinated pathway for technology transfer, process development, clinical manufacturing, and future commercial supply.
The Beauvais facility will offer flexible manufacturing across multiple scales, enabling MH002 and other pipeline programs to progress through development, later-stage clinical manufacturing, and, ultimately, commercial-scale production.
Capacity supporting CORAL programs is set to expand in line with the clinical and commercial progress of MRM Health's portfolio. Per the timeline outlined by the companies, initial process development and pilot manufacturing activities are to begin by 2027, with commercial-scale manufacturing targeted from 2030.
Clinical Context and Industrial Stakes
MRM Health is a clinical-stage biotech developing live biotherapeutic products for immune-mediated diseases with high unmet needs.
Its lead program, MH002, targets inflammatory bowel diseases and is currently being evaluated in the 204-patient STARFISH-UC Phase 2b study in patients with the indication, according to the company's announcement. The new manufacturing partnership follows the collaboration the two companies launched last year, a relationship referenced by Biocodex's chief executive.
With the agreement in place, the companies position the Beauvais site as an additional pathway for MH002 and other MRM Health programs as they move from clinical development toward potential commercial supply.
The deal reflects a broader emphasis within the live biotherapeutics field on industrialization capacity, which the companies identify as a critical requirement given the complexity of manufacturing products based on live bacterial consortia.
For MRM Health, the arrangement secures access to dedicated anaerobic manufacturing infrastructure without requiring its own capital investment. For Biocodex, it extends the company's more than 70 years of involvement in the microbiome field into manufacturing services for next-generation live biotherapeutic products.
Tracked in the database
New Manufacturing Facility/Plant Expansion · Europe
New Manufacturing Facility/Plant Expansion
Europe
Chemical
5 November 2026
4 min read
Tagged
Also read
Pathos AI Teams Up With Bristol Myers Squibb and Tempus AI to Expand AI-Driven Neuroscience Research
Orion Pharma Invests Over $112 Million to Upgrade Four Finland Manufacturing Sites
Biocon Secures European Commission Approval for Pertuzumab Biosimilar Pebrilzo in HER2-Positive Breast Cancer
Live from the tracker
The projects behind these stories
Capacity, capex, stage, contractors and verified contacts for every project we track, updated daily.